Seeking Alpha

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its...

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its treatment therapy for patients with severely calcified coronary lesions had exceeded expectations by a significant margin. The study is reviewing the safety and effectiveness of it's orbital atherectomy technology and is the first Investigational Device Exemption study to seek approval for treating these lesions.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|